The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease  by Ng, Li Fang et al.
Original Contribution
The mitochondria-targeted antioxidant MitoQ extends lifespan and
improves healthspan of a transgenic Caenorhabditis elegans model of
Alzheimer disease
Li Fang Ng a, Jan Gruber a,b,n, Irwin K. Cheah a, Chong Kit Goo a, Wei Fun Cheong c,
Guanghou Shui d, Kim Ping Sit a, Markus R. Wenk c, Barry Halliwell a
a Department of Biochemistry, National University of Singapore, Singapore 117597, Singapore
b Yale-NUS College, 6 College Avenue East, Singapore 138614, Singapore
c Life Sciences Institute, National University of Singapore, 28 Medical Drive, Singapore 117456, Singapore
d State Key Laboratory of Molecular Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences,
Beijing 100101, China
a r t i c l e i n f o
Article history:
Received 22 November 2013
Received in revised form
17 February 2014
Accepted 3 March 2014
Available online 15 March 2014
Keywords:
Mitochondria-targeted antioxidants
MitoQ
Alzheimer disease
Caenorhabditis elegans
β-Amyloid peptides
Oxidative stress
Lifespan
Healthspan
Cytochrome c oxidase
Complex IV
Cardiolipin
Electron transport chain
Free radicals
a b s t r a c t
β-Amyloid (Aβ)-induced toxicity and oxidative stress have been postulated to play critical roles in the
pathogenic mechanism of Alzheimer disease (AD). We investigated the in vivo ability of a mitochondria-
targeted antioxidant, MitoQ, to protect against Aβ-induced toxicity and oxidative stress in a Caenorhabditis
elegans model overexpressing human Aβ. Impairment of electron transport chain (ETC) enzymatic activity
and mitochondrial dysfunction are early features of AD. We show that MitoQ extends lifespan, delays
Aβ-induced paralysis, ameliorates depletion of the mitochondrial lipid cardiolipin, and protects complexes
IV and I of the ETC. Despite its protective effects on lifespan, healthspan, and ETC function, we ﬁnd that
MitoQ does not reduce DCFDA ﬂuorescence, protein carbonyl levels or modulate steadystate ATP levels or
oxygen consumption rate. Moreover, MitoQ does not attenuate mitochondrial DNA (mtDNA) oxidative
damage. In agreement with its design, the protective effects of MitoQ appear to be targeted speciﬁcally to
the mitochondrial membrane and our ﬁndings suggest that MitoQ may have therapeutic potential for
Aβ- and oxidative stress-associated neurodegenerative disorders, particularly AD.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Alzheimer disease (AD)1 is a progressive, age-related neurode-
generative disease and is the most common form of dementia
globally [1,2]. It is becoming an increasingly serious public health
concern, especially in countries with rapidly aging populations.
Currently, the prevalence of AD is estimated to be approximately
34 million people worldwide and this ﬁgure is expected to triple
over the next 40 years [2]. The cost of caring for AD patients today
is estimated to exceed USD $200 billion annually in the United
States alone. If no disease-modifying therapies are developed, this
cost is projected to increase to over USD $1.2 trillion by the year
2050 [3].
Aβ peptides are a family of peptides produced by sequential
cleavage of a large amyloid precursor protein (APP) via β- and
γ-secretase enzymes [4]. The “amyloid hypothesis” states that
accumulation of Aβ is integral to AD pathogenesis. It is believed
that the presence of Aβ plays a key role in the synaptic damage
and neuronal loss that characterize AD [5,6]. Cleavage of APP
leading to the production of Aβ between 39 and 43 residues in
length [4] is of particular importance as peptides of this size
readily aggregate and form senile plaques [1,4–6].
Oxidative stress is closely associated with Aβ accumulation and
is believed to play a crucial role in AD pathogenesis [7–10].
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Reactive oxygen species (ROS) are continuously produced as by-
products of normal mitochondrial electron transport and mitochon-
dria may also be a primary site of ROS-mediated oxidative damage
[11,12]. Under normal conditions, most ROS are scavenged by
antioxidant defense systems. However, factors that disrupt the
prooxidant–antioxidant balance in favor of the former can lead to
elevated damage to nucleic acids, proteins, and lipids. In the brain,
such imbalance in ROS homeostasis can lead to neuronal damage and
this may contribute to the pathogenesis of AD [7,8,13,14]. In 1994,
Butterﬁeld and colleagues showed that Aβ peptides can initiate
neuronal lipid peroxidation [9,15]. AD patients also suffer from
increased levels of lipid peroxidation [16], increased formation of
advanced glycation end products [17], elevated protein nitration [18],
and increased levels of oxidative DNA damage markers [19].
Apart from directly promoting oxidative damage, there is
evidence that Aβ targets the mitochondria, causing impairment
of ETC complexes, elevation in ROS production, and mitochondrial
dysfunction [20,21]. Interestingly, several studies have reported
that Aβ is actively imported into mitochondria through cellular
trafﬁcking systems [20]. Manczak and co-workers [21] showed
that Aβ readily penetrates the mitochondria and localizes to
mitoplasts, where the ETC complexes reside. This localization is
in line with the ﬁnding that Aβ inhibits complex IV of the ETC
[22,23]. Indeed, early signs of AD include decreased respiratory
chain enzyme activity and reduced mitochondrial membrane
potential [24,25]. In addition, Aβ may further contribute to
mitochondrial dysfunction through disruption of mitochondrial
fusion and ﬁssion processes, leading to mitochondrial fragmenta-
tion [26].
Given the evidence that oxidative stress plays an important role
in Aβ-induced pathogenesis of AD, therapeutic efforts aimed at the
removal of free radicals, prevention of their formation, or restora-
tion of ETC function seem promising. Indeed, numerous studies
have been carried out with the aim of doing this. Vitamin E,
ﬂavonoids, and curcumin have been tested in AD patients [14,27,28]
but most have failed to show any beneﬁcial effects on cognitive tests.
However, a promising new class of compounds is the mitochondria-
targeted antioxidants. For instance, MitoQ (mitoquinone mesylate:
10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cycloheexadienlyl)decyl-
triphenylphosphonium methane sulfonate), one of the best character-
ized mitochondria-targeted antioxidants, has been reported to
prevent cognitive decline and early neuropathology in one study
using a transgenic mouse model of AD [29]. MitoQ is a mitochondria-
targeted ubiquinol, produced by covalently attaching a ubiquinone
moiety to the lipophilic decyltriphenylphosphonium (dTPP) cation
through a 10-carbon aliphatic carbon chain [30]. MitoQ is designed
to selectively concentrate several hundred-fold in the mitochondrial
matrix due to the large mitochondrial membrane potential [29–32].
The ubiquinone moiety of MitoQ is then inserted into the lipid bilayer
of the mitochondrial matrix and rapidly reduced by complex II to
ubiquinol, which acts as the active antioxidant. This ubiquinol moiety
is continuously recycled to the active antioxidant by the respiratory
chain [30,33]. MitoQ has been speciﬁcally designed with the aim
of protecting the mitochondrial membrane against lipid peroxidation
[34].
To directly evaluate the efﬁcacy of MitoQ in Aβ-induced
pathology, we employed a transgenic Caenorhabditis elegans strain
(CL2006) expressing high levels of human Aβ under a muscle-
speciﬁc promoter [35]. This transgenic AD model relates Aβ
expression and cellular toxicity to an easily visible progressive
paralytic phenotype, greatly facilitating pharmacological evalua-
tion of intervention strategies [35,36]. CL2006 is an ideal model to
investigate the therapeutic potential of drugs for treating AD,
as this strain constitutively expresses Aβ.
Here, we describe the mitochondria-speciﬁc pharmacological
effects of MitoQ in protecting against Aβ-induced toxicity and
oxidative stress by examining the effect of MitoQ on Aβ-expressing
nematodes. We administered compounds to nematodes and
performed assays at early ages (day 6) because increasing evidence
demonstrates that Aβ-induced oxidative stress and mitochondrial
dysfunction precede the development of amyloid plaques [37–39]
and contribute early in AD pathogenesis [40,41]. For this reason,
mitochondria-targeted therapeutic interventions at this early
stage of the disease may be effective in delaying AD progression
and can be the key to counteract the early increased
Aβ-induced toxicity and oxidative stress. In fact, clinical trials of
these therapies may be hampered by the limitations that patients
recruited are typically at the late stage of disease. Here, we found
that early administration of MitoQ prolonged the lifespan of
Aβ-expressing transgenic C. elegans, delayed Aβ-induced paralysis,
and that these observations were related to the protection of key
mitochondrial ETC complexes, possibly due to preservation of
cardiolipin content.
Materials and methods
General maintenance of C. elegans
The transgenic nematode strain CL2006 (unc-54/Aβ1–42) and
wild type (N2) were used in this study. The nematodes were
propagated at 20 1C on nematode growth medium (NGM) agar
plates. Age-synchronized animals were prepared by hypochlorite
treatment. MitoQ and dTPP stock solutions were prepared in
deionized water and ﬁlter-sterilized before being added into
NGM agar and Escherichia coli OP50-1 to the desired ﬁnal con-
centration of 1 mM. Young adults (day 4 post-hatching) were then
transferred and cultured on NGM plates with or without addition
of treatment compounds until harvest. All experiments reported
here were performed using day 6 adult worms and at least three
independent studies for each assay.
Blinded lifespan and healthspan studies
Lifespan and healthspan of C. elegans were performed under
blinded conditions to eliminate experimental bias [42]. A total
initial population of 200 worms was tested for each treatment
condition. Worms were counted and transferred to fresh plates
every 2 days until the postegg-laying period to prevent contam-
ination by progeny. For the healthspan study, worms were scored
for locomotor activity following the scoring framework reported
by Herndon et al. [43] with modiﬁcations. Brieﬂy, CL2006 worms
were subdivided into two groups: “nonparalyzed” animals were
healthy, were highly mobile, showed constant movement, and
rotated around their longitudinal axis, whereas “paralyzed” ani-
mals moved only their head or tail in response to prodding. The
motility of wildtype N2 C. elegans that responded to prodding was
scored according to their activity level as A, B, or C, following the
same scoring criteria proposed by Herndon et al. [43]. Class A
animals were healthy, showed spontaneous movements, class B
animals produced non-sinusoidal tracts but moved only when
prodded, whereas class C animals showed only head or tail
movement when prodded.
ROS measurement in C. elegans
General ROS production in whole animals was measured
using 2,7-dichloroﬂuorescein diacetate (DCFDA; Sigma–Aldrich,
St. Louis, MO, USA) as previously described [44,45]. One hundred
worms were transferred into each well of a black 96-well micro-
titer plate containing 100 ml of M9 buffer and 50 mM DCFDA. ROS-
associated ﬂuorescence levels were read every 2 min for 14 h
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using a ﬂuorescence plate reader (SpectraMax Gemini EM, Mole-
cular Devices) at excitation 485 nm and emission 520 nm at room
temperature.
Protein carbonyl content (PCC) determination
PCC determination was conducted as described in [46]. Two
hundred worms were sonicated and soluble protein concentra-
tions of the lysates were determined using a Bradford protein
assay (Bio-Rad Laboratories, Hercules, CA, USA). For each sample,
2 mg of protein was derivatized and loaded into a slot blot
apparatus (Bio-Rad). The blocked membrane was probed with
anti-dinitrophenylhydrazine primary antibody (1:150), followed by
secondary detection with an anti-rabbit horseradish peroxidase-
conjugated IgG antibody (1:300). Antibody-bound proteins were
detected by chemiluminescence using a chemiluminescence sub-
strate mixture (Pierce Biotechnology, Thermo Fisher Scientiﬁc,
Waltham, MA, USA).
Adenosine-50-triphosphate (ATP) measurement
The ATP assay was performed as described in [45]. Two
hundred worms were collected, lysed in 10% trichloroacetic acid
by sonication (Soniclean, Thebarton), and centrifuged at 15,000g at
4 1C for 5 min. ATP standards and supernatants of samples were
pipetted into the wells of a white 96-well microtiter plate, followed
by the addition of arsenite ATP buffer. ATP levels were measured
using a luminometer (Inﬁnite 200, Tecan, Männedorf, Switzerland)
preprogrammed to inject ﬁreﬂy lantern extract (2 mg/ml).
Oxygen consumption measurement
Oxygen consumption for whole C. elegans was assayed using a
Clark-type electrode (Hansatech oxygen electrode, Hansatech
Instruments) as previously described [45]. Brieﬂy, worms in 1 ml
M9 buffer were placed in the chamber of the Clark-type electrode.
The amount of oxygen consumed was monitored polarographically
for 2–15 min and corrected against changes in oxygen concentra-
tion of the bacterial control. Oxygen consumption rates were
normalized to protein concentration, which was measured using
the DC-protein assay (Bio-Rad).
Sequence-speciﬁc mtDNA damage
Sequence-speciﬁc mtDNA damage was assessed in a 6.3 kb
region of the mitochondrial genome using sybr green dye (primers
sequence taken from [47]) and 71 bp region using Taqman probe
with forward primer (GAGCGTCATTTATTGGGAAGAAGA) and
reverse primer (TGTGCTAATCCCATAAATGTAACCTT) by performing
quantitative real-time PCR (qRT-PCR) as previously described in
[45]. Mitochondria were extracted and puriﬁed using Prepman
Ultra Sample Preparation Reagent (Applied Biosystems, Foster City,
California, USA), according to the manufacturer’s protocol. qRT-PCR
was performed using GeneAMP XL PCR kit (applied Biosystems)
based on the protocol in [45].
Measurement of complex IV (cytochrome c oxidase) activity
of the ETC
Mitochondria were isolated as previously described [48]. Com-
plex IV activity was measured using a polarographic assay mod-
iﬁed from [49] and normalized to mtDNA copy number according
to [45]. The assay was started by adding sequentially 65–70 mg of
reduced cytochrome c in Mir05 buffer, 10 mg of mitochondrial
protein, and 5 mM azide. The azide-sensitive oxygen consumption
measured complex IV activity after background subtraction of
autoxidation of reduced cytochrome c (unpublished data). A high-
resolution respiratory system (Oroboros, Oxygraph-2k) was used.
Measurement of complex I (NADH dehydrogenase) activity of ETC
Isolation of the mitochondria was carried out as previously
described [48]. The enzyme activity of complex I was measured by a
decrease in ﬂuorescence of NADH at ex/em 352 nm/464 nm using
decylubiquinone as an electron acceptor [50] and normalized to
mtDNA copy number according to [45]. Mitochondrial protein
(10 mg) was added to a respiratory buffer of pH 7.2 containing
25 mM KH2PO4, 2 mM NaN3, 5 mMMgCl2, 64 mM decylubiquinone,
2 mg/ml albumin, and 25 mM NADH. Complex I activity was
determined from the difference in NADH oxidation before and after
rotenone inhibition.
Analysis of lipids using high-performance liquid chromatography–
mass spectrometry (LC–MS)
Lipid extraction was performed with a modiﬁcation of the
Bligh and Dryer double chloroform extraction method [51]. Lipid
analysis was performed according to [45]. Brieﬂy, worms were
homogenized in chloroform:methanol (1:2; v/v) and incubated on
ice with agitation for 2 h. After incubation, ice-cold chloroform
and ice-cold water were added and the ﬁrst extract was collected
from the lower organic layer. Ice-cold chloroform was added for
re-extraction. The lower organic extracts were pooled and dried
under a stream of N2 and stored at 80 1C. Lipid species were
identiﬁed and quantiﬁed using a high-performance liquid chroma-
tography 1200 system coupled with an Applied Biosystems triple-
quadrupole/ion trap mass spectrometer (3200 QTrap). Lipids were
quantiﬁed using spiked internal standards. PC-14:0/14:0, PE-14:
0/14:0, CL-15:0(3)/16:1, and C12-SM standards were obtained from
Avanti Polar Lipids (Alabaster, AL, USA)
Statistical analysis
For statistical analysis, GraphPad Prism version 5.02 for Microsoft
Windows (GraphPad Software, San Diego, CA, USA) was used. Life-
span and healthspan curves were analyzed by plotting Kaplan–Meier
survival curves and conducting log-rank tests. All other data were
plotted as means7SEM, analyzed using ANOVA and Bonferroni's
multiple comparisons post-test unless otherwise stated. Differences
with p o 0.05 were considered statistically signiﬁcant.
Results
MitoQ decreases the mortality associated with Aβ-induced toxicity
in transgenic C. elegans
The aim of this study was to examine the ability of the
mitochondria-targeted antioxidant MitoQ to modulate Aβ-induced
toxicity and oxidative stress in a transgenic C. elegans model in
which the expression of the human Aβ peptide in the body-wall
muscle causes progressive paralysis [35,36]. We ﬁrst tested the
ability of MitoQ to modulate lifespan and healthspan in this strain
by conducting a blinded dose–response study at MitoQ concentra-
tions of 0.1, 1, and 5 mM. We aimed to identify the lowest MitoQ
concentration resulting in optimal lifespan effects. However, the
lipophilic cation dTPP (the targeting moiety of MitoQ without the
ubiquinone antioxidant group) at high concentration has been
shown to promote mitochondrial depolarization [29,52]. In order
to control for nonspeciﬁc effects of dTPP on the survival of
C. elegans, we therefore carried out dTPP-only control experiments
at the same concentrations [29,52]. In addition to the dTPP controls,
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a negative control experiment in the absence of both MitoQ and
dTPP was carried out.
Our initial pilot study showed that C. elegans cultured with 1 and
5 mMMitoQ displayed signiﬁcant lifespan extension effects relative to
untreated control (Table 1, Figs. 1A–C). The mean lifespan of animals
treated with both 1 and 5 mMMitoQ was signiﬁcantly extended (p o
0.01 for both 1 and 5 mM MitoQ; Table 1, Figs. 1B and C), whereas
0.1 mM MitoQ showed no signiﬁcant lifespan effect (Fig. 1A). Surpris-
ingly, administration of 0.1 mM dTPP was also associated with a
signiﬁcant (p o 0.01) increase in mean lifespan (Table 1, Fig. 1A) in
this experiment. In contrast to 0.1 mM dTPP, 1 and 5 mM dTPP had no
signiﬁcant beneﬁt on lifespan (Table 1, Figs. 1B and C). The results
from the pilot study indicated that administration of higher
concentration of MitoQ (5 mM) had no additional beneﬁt to this
transgenic strain, with both 1 and 5 mM MitoQ showing similar
lifespan extension (Table 1). This suggested to us that 1 mM MitoQ
might be the lowest concentration that displayed optimal lifespan
extension effect.
We carried out a second lifespan study at 0.1 and 1 mM MitoQ
and dTPP (Table 1, Figs. 1D and E). Similar to our initial pilot
lifespan study, administration of 1 mM MitoQ showed consistent
lifespan-prolonging effect (p o 0.01; Table 1, Fig. 1E) and 0.1 mM
MitoQ did not extend the lifespann. However, no lifespan exten-
sion was observed in animals treated with either 0.1 or 1 mM dTPP
in this second lifespan study (Table 1, Figs. 1D and E). Because
1 mM MitoQ appeared to be at the lower end of the beneﬁcial dose
Table 1
Mean lifespan from two independent experiments, A and B
Dose Lifespan study A Lifespan study B
Mean lifespan7SEM (days) p Mean lifespan7SEM (days) p
Control 13.270.4; n ¼ 145 12.070.4; n ¼ 169
0.1 mM MitoQ 13.870.4; n ¼ 148 ns 12.370.4; n ¼ 162 ns
0.1 mM dTPP 15.270.4; n ¼ 155 o0.01 11.870.4; n ¼ 165 ns
1 mM MitoQ 15.070.4; n ¼ 161 o0.01 14.070.4; n ¼ 162 o0.01
1 mM dTPP 14.770.4; n ¼ 158 ns 12.570.4; n ¼ 155 ns
5 mM MitoQ 15.270.5; n ¼ 148 o0.01
5 mM dTPP 13.770.4; n ¼ 148 ns
All lifespan studies were performed under blinded conditions. Treatment signiﬁcantly affected mean lifespan in both dose–response studies
(A and B) (p o 0.01 for both lifespan studies, ANOVA). At each concentration, mean lifespan for MitoQ and dTPP vs untreated control animals
was analyzed using ANOVA with Bonferroni's post-test, mean±sem. In study A, only administration of 1 and 5 mM MitoQ or 0.1 mM dTPP
signiﬁcantly extended mean lifespan. 0.1 mM MitoQ and 1 and 5 mM dTPP had no signiﬁcant beneﬁt on lifespan. In the repeat study, study B,
only 1 mM MitoQ signiﬁcantly extended mean lifespan. While administration of 0.1 mM MitoQ or 0.1 or 1 mM dTPP did not extend the
nematodes' lifespan. ns, not signiﬁcant.
Fig. 1. Dose–response survival study of CL2006 transgenic C. elegans treated with various concentrations of MitoQ or dTPP (n ¼ 200 worms per condition). Survival
curves from each condition were compared to that of the untreated control, analyzed using log-rank (Mantel–Cox) test. (A–C) Life-span study A. (A) Nematodes
treated with 0.1 mM MitoQ did not show lifespan extension but 0.1 mM dTPP signiﬁcantly extended nematodes' survival (p o 0.01). (B) Nematodes treated with 1 mM MitoQ
or dTPP showed signiﬁcant lifespan extension although dTPP was less signiﬁcant (p o 0.01 and p o 0.05, respectively). (C) Administration of 5 mM MitoQ also signiﬁcantly
extended lifespan (p o 0.001) but 5 mM dTPP did not increase survival. (D and E) Lifespan study B. (D) Nematodes administered with 0.1 mM MitoQ or dTPP did not show
increased survival. (E) Nematodes treated with 1 mM MitoQ showed signiﬁcantly increased survival (p o 0.01), whereas administration of 1 mM dTPP did not increase
nematodes' survival.
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range that could consistently extend lifespan, all future experi-
ments were performed using 1 mM MitoQ and 1 mM dTPP.
We carried out a further independent experiment and found
that administration of 1 mM MitoQ again led to a signiﬁcant
lifespan extension (p o 0.01), whereas the lifespan of the dTPP-
treated animals did not show any signiﬁcant difference at 1 mM
concentration (Fig. 2A). MitoQ prolonged mean lifespan by about
9% (Fig. 2B) compared to dTPP and this effect was statistically
signiﬁcant (p o 0.0001). Another parameter, maximum lifespan,
which is deﬁned as the average lifespan of the top 10% of the
longest surviving animals, was also signiﬁcantly extended in the
MitoQ-treated animals compared to both untreated and dTPP-
treated control animals (Figs. 2C, p o 0.0001). The observation
that lifespan of dTPP only animals was not extended supports the
notion that the lifespan extension in the animals treated with
1 mM MitoQ was dependent on the ubiquinone moiety.
Finally, in order to investigate the efﬁcacy of MitoQ as an aging
modulator more generally, we also conducted a parallel lifespan
study using 1 mM MitoQ or dTPP in wildtype N2 C. elegans.
In contrast to the transgenic animals, we did not detect any
signiﬁcant overall differences in the survival between the
untreated-, MitoQ-treated, and dTPP-treated wildtype animals
(Fig. 2D). MitoQ showed positive effects in Aβ-overexpressing
CL2006 animals but had no effect on wildtype animals, suggesting
that MitoQ may be beneﬁcial under stressed or diseased
conditions.
MitoQ delays Aβ-induced paralysis in transgenic C. elegans
Lifespan modulation alone is of limited interest and is not a
reliable indicator of overall health status. In addition to lifespan
experiments, we therefore conducted a blinded healthspan study
in which we measured the animal motility as an indicator of
health. Healthspan is an index of physiological capacity, meaning
the period of time during which the animals are able to maintain
good health [46]. The transgenic C. elegans strain also carries the
rol-6 gene, which causes the animals to rotate around their
longitudinal axis instead of the coordinated sinusoidal movement.
Due to the nature of this movement, only two classes of locomo-
tion were scored in this transgenic strain: non-paralyzed and
paralyzed. Non-paralyzed animals were scored as healthy, whereas
animals that moved only the head or tail in response to prodding
were scored as paralyzed [43,46,53]. As expected, the health
status of the nematodes declined as they aged. However,
a signiﬁcant (p o 0.0001) delay in onset of paralysis was observed
in animals treated with MitoQ (Fig. 3A). On day 6, 82% of untreated
control animals were nonparalyzed, whereas 95% of MitoQ-treated
and 93% of dTPP-treated animals were nonparalyzed. At day 10, 77,
Fig. 2. Lifespan study C, survival of CL2006 transgenic C. elegans in the presence of 1 lMMitoQ, dTPP, or vehicle (n ¼ 200 worms per condition). (A) As expected from the
dose–response studies, MitoQ extended the lifespan of transgenic animals; log-rank test showed a signiﬁcant difference between 1 mMMitoQ and untreated control (p o 0.01).
Mean and maximum lifespan average from the three independent experiments, analyzed using ANOVAwith Bonferroni's post-test, mean7SEM, are shown. (B) Combined data
show that nematodes treated with MitoQ had signiﬁcant mean lifespan extension of 14% compared to the untreated control animals (***p o 0.0001); dTPP did not extend mean
lifespan of the transgenic animals. **p o 0.01. (C) A signiﬁcant maximum lifespan extension of 9% was observed in animals treated with MitoQ (p o 0.0001) relative to
untreated control animals; dTPP did not extend the maximum lifespan of the animals. (D) Survival curve of wild-type C. elegans treated with MitoQ or dTPP and untreated
control wild-type animals. No signiﬁcant differences in the survival function of the untreated, MitoQ-treated, and dTPP-treated wild-type animals were detected.
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70, and 50% of MitoQ-treated, dTPP-treated, and untreated
animals, respectively, remained healthy (non-paralyzed). The sig-
niﬁcant healthspan advantage even in dTPP-treated animals illus-
trates that dTPP also delayed paralysis in the animals, although
somewhat less than MitoQ. In summary, MitoQ-treated animals are
healthier, p o 0.0001 (Fig. 3B). Even at the later stages, at which
only 10% of animals remained non-paralyzed (maximum health-
span), we found that MitoQ signiﬁcantly improved the maximum
healthspan compared to both untreated and dTPP-treated nema-
todes (p o 0.0001; Fig. 3C). In contrast to CL2006 animals, we also
monitored nematode healthspan inwildtype N2 C. elegans. Similar to
the lifespan study, MitoQ treatment did not alter the mobility of the
wildtype C. elegans (Fig. 3D). The lack of lifespan and healthspan
improvement in the MitoQ-treated wildtype nematodes further
corroborates the theme of antioxidants working under stress condi-
tions [33].
MitoQ does not affect global oxidative stress
In order to answer the question whether the observed lifespan
increase and healthspan improvement (Figs. 2 and 3) were
associated with a reduction in global oxidative stress, we exam-
ined ROS production rate and total protein carbonyl content of
untreated control, MitoQ- and dTPP-treated animals. We
employed the DCFDA method in whole C. elegans to explore the
efﬁcacy of MitoQ in modulating global ROS level. However, MitoQ
treatment did not signiﬁcantly reduce the ROS production rate
relative to untreated control and dTPP-treated animals (Fig. 4A).
These data may be taken to indicate that MitoQ had no effect on
the global ROS ﬂux in the transgenic nematodes. However, there
are several well-known limitations of the DCFDA assay [54–56]. In
the present experiments, we measured DCFDA ﬂuorescence in
intact animals using our whole nematode DCFDA assay. We have
previously validated this use of the DCFDA dye in our laboratory,
showing for example, a reproducible, mild, age-dependent
increase in this signal when used in whole worms [45]. Lysing
worms or cells, in contrast, will cause the release of transition
metal ions such as iron and these may participate in redox cycling
thereby generating more ROS and leading to overestimation of
ROS levels. When cells are not disrupted, iron remains seques-
tered, avoiding this particular set of artifacts [54–57]. However, we
also note other, well-known limitations and potential artifacts
associated with this DCFDA assay. First, DCFDA clearly is not a
speciﬁc measure of peroxide generation but may at best provide
an indication of global ROS production [54,56]. Even for this
purpose this assay should be approached with caution, as high
DCFDA level, intermediate DCF radical formation, and cytochrome
c all can cause artifactual DCFDA ﬂuorescence signals [56,58].
The presence of oxidized protein can modify key enzymes and
structural proteins, and has been suggested to be a key component
of the neurodegenerative process in AD [59]. To investigate the
efﬁcacy of MitoQ in modulating this process, we measured protein
Fig. 3. Healthspan of the surviving CL2006 transgenic animals treated with MitoQ, dTPP, or vehicle (n ¼ 200 worms per condition). (A) Healthspan curve from a single
experiment, representative of n ¼ 3 independent experiments. MitoQ-treated animals remained healthy for a longer period of time (p o 0.0001, log-rank (Mantel–Cox)
test). Mean and maximum healthspan average from three independent experiments, analyzed using ANOVA with Bonferroni's post-test, mean7SEM, are shown. (B) MitoQ
treatment extended mean healthspan by 13% compared to untreated control animals (p o 0.0001). (C) MitoQ treatment signiﬁcantly extended the maximum healthspan of
the transgenic animals by 7% relative to the untreated control animals (p o 0.0001). (D) Healthspan curve of wildtype C. elegans treated with MitoQ or dTPP and untreated
control wildtype animals. No signiﬁcant differences in the health progression of the untreated, MitoQ-treated, and dTPP-treated wild-type animals were detected.
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carbonyl levels as a marker of protein oxidation. Fig. 4B and
Supplementary Fig. 1 show the carbonyl levels in untreated control
and MitoQ- and dTPP-treated animals. Consistent with our DCFDA
results, the levels of carbonyls were similar in all three treatment
groups, showing that neither MitoQ nor dTPP signiﬁcantly atte-
nuated total protein carbonyl level in this transgenic strain.
MitoQ treatment does not affect the mtDNA damage burden
As MitoQ is an antioxidant that is speciﬁcally designed to
deliver its antioxidant moiety to mitochondria, we next deter-
mined the oxidative damage burden in mitochondria. Several lines
of evidence suggest an elevation of oxidative damage to DNA in
AD, subsequently causing mitochondrial dysfunction and neuronal
death [19,60]. To test the potential of MitoQ to modulate oxidative
DNA damage to mtDNA in CL2006 transgenic C. elegans, we
applied a sequence-speciﬁc mtDNA damage assay [45]. Although
there appeared to be a slight trend toward lower mtDNA damage
in MitoQ-treated animals compared to the untreated control
animals, this decrease was not statistically signiﬁcant (Fig. 5A).
MitoQ does not alter global energy metabolic parameters
Our experiments demonstrated that neither global oxidative
damage nor mtDNA damage differs signiﬁcantly between untreated
controls and CL2006 supplemented with MitoQ or dTPP (Figs. 4 and
5A). This was surprising given that we observed signiﬁcant lifespan
and healthspan extension with MitoQ treatment (Figs. 2 and 3). To
explore this discrepancy further, we next determined mitochondrial
metabolism and energy availability by measuring the oxygen
consumption rate and steady-state ATP content of CL2006 animals.
However, we detected no signiﬁcant difference in the ATP content of
untreated control, MitoQ- and dTPP-treated animals (Fig. 5B).
Although there was a trend toward lower ATP content in dTPP-
treated animals compared to the untreated control and MitoQ-
treated animals, this reduction was not statistically signiﬁcant.
Similarly, we found that neither MitoQ nor dTPP had any signiﬁcant
effect on oxygen uptake (Fig. 5C). Overall, there was no difference in
these parameters of global metabolism between the three treat-
ment groups, suggesting that MitoQ did not modulate the global
mitochondrial metabolism and was not able to increase the mito-
chondrial energy supply. However, the ATP levels reported represent
steady-state levels and ATP can also be produced by glycolysis.
However, oxygen uptake was also unaltered.
MitoQ protects complex IV and complex I of the ETC
MitoQ was designed as an antioxidant to accumulate within
mitochondria and is supposed to protect the mitochondrial
membrane against oxidative damage. Therefore, we further
investigated the ability of MitoQ to protect mitochondria and
mitochondrial function more locally in the mitochondrial mem-
brane. We thus examined the function of the ETC protein
complexes IV and I.
Numerous studies have reported that complex IV activity is
decreased in AD tissues [24,61–63]. Complex IV is the membrane-
bound terminal complex of the ETC that catalyzes the transfer of
electrons from cytochrome c to oxygen [64]. A sensitive complex
IV activity assay was therefore conducted in mitochondrial
extracts using a polarographic assay that measures complex IV
activity. We detected a signiﬁcant elevation of complex IV activity
relative to both control groups only in MitoQ-treated animals
(Figs. 6A, p o 0.01). A spiking assay, using several concentrations
of MitoQ, was tested for any direct effect of MitoQ or related
artifacts on this complex IV activity assay. We found that spiking
did not change the level of complex IV activity detected (data not
shown). This conﬁrms that MitoQ did not directly interfere with
the complex IV activity measurement, and hence, the increase in
complex IV activity was due to the protective effect of MitoQ on
the complex IV function in the mitochondria.
Since complex I is the primary site of superoxide generation in
the ETC, releasing superoxide to the inner mitochondrial matrix
[58,65,66], we further explored the efﬁcacy of MitoQ in modulating
the ETC key enzyme complexes by measuring complex I activity in
CL2006 animals. We found that MitoQ as well as dTPP treatment
signiﬁcantly increased the complex I activity (Figs. 6B, p o 0.01)
compared to untreated control animals. In fact, we observed a non-
signiﬁcant trend toward higher complex I activity (about 9%) in
dTPP-treated animals compared to MitoQ-treated animals, implying
that the increase in complex I activity observed in both MitoQ and
dTPP treatment could be due to the mild uncoupling effect of
the dTPP moiety and not the antioxidant ubiquinone moiety. Similar
to complex IV, we conducted a spiking assay and conﬁrmed
that neither MitoQ nor dTPP interfered directly with the complex
I assay.
In summary, MitoQ signiﬁcantly elevated complex IV activity,
whereas both MitoQ and dTPP signiﬁcantly improved complex I
activity, suggesting that MitoQ treatment either protected or
promoted activity of the ETC complexes positioned in the mito-
chondrial membrane.
Fig. 4. MitoQ did not attenuate global oxidative stress. (A) Generalized ROS
production rate measured using wholeworm DCFDA assay in intact animals. MitoQ
and dTPP had no signiﬁcant effect on the global ROS ﬂux relative to untreated control
animals (p 4 0.5, ANOVA, mean7SEM), n ¼ 3 independent experiments. (B) Relative
protein carbonyl content normalized to worm protein from ﬁve independent experi-
ments, measured by a densitometric analysis of the slot-blot intensity. Protein carbonyl
contents of the three treatment groups were not signiﬁcantly different (p 4 0.5,
ANOVA, mean7SEM), n ¼ 20 independent replicates.
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MitoQ increases cardiolipin content of mitochondrial membranes
Changes in enzyme activity of the mitochondrial ETC can be
secondary to changes in mitochondrial lipid, particularly a
decrease in cardiolipin content in the mitochondrial matrix
[62]. Cardiolipin is one of the lipid components of the ETC,
interacting with ETC proteins to regulate mitochondrial function
[67]. We employed a lipidomics method [45] to characterize
mitochondrial cardiolipin species and determine the level of
each cardiolipin species in untreated control, MitoQ- and dTPP-
treated animals. Overall, global cardiolipin levels appeared to be
higher in MitoQ-treated animals but this trend was not statisti-
cally signiﬁcant (Fig. 7A). We further assessed the levels of
individual cardiolipin species, ﬁnding that MitoQ treatment
tended to increase the amount of cardiolipin in most cardiolipin
species that we examined, particularly CL78, CL79, and CL80
(Fig. 7B). Interestingly, within the cardiolipin species, we found
that MitoQ treatment signiﬁcantly increased especially highly
unsaturated cardiolipin species (20:4) (Fig. 7B). Among these
unsaturated cardiolipin species, we consistently detected a
signiﬁcant, at least 16%, elevation (CL80:16, CL79:14, CL78:15; p o
0.05, p o 0.01, p o 0.01, respectively). As highly unsaturated
cardiolipin is more vulnerable to oxidative damage because of its
polyunsaturated fatty acid structure [62], these data are consistent
with the notion that MitoQ administration may protect the mitochon-
drial membranes, speciﬁcally highly unsaturated cardiolipin species
from oxidative damage. Moreover, the increase in cardiolipin content
is consistent with the higher ETC activity that we observed in
complexes IV and I in MitoQ-treated animals, suggesting that MitoQ
may protect mitochondrial lipids and associated lipid-bound ETC
complexes.
Discussion
The development of compounds that selectively target antiox-
idant active groups to mitochondria provides an opportunity to
manipulate and protect mitochondrial function. These compounds
may become an important tool in the development of therapies for
aging-related disorders associated with mitochondrial dysfunction
[31,47]. Antioxidants have been investigated as a strategy to
attenuate the impact of aging and to extend lifespan [44]. How-
ever, untargeted antioxidants often fail to modulate lifespan,
possibly because only a small fraction of these antioxidant mole-
cules is taken up by the mitochondria. Here, we show that
exposure to MitoQ prolongs the lifespan of transgenic
Aβ-overexpressing nematodes. In our experiments, MitoQ not
only increased lifespan but also promoted healthspan. Improved
healthspan is important, representing one of the most relevant
clinical, social, and economic outcomes of neurodegenerative and
aging research [68]. Overall, our results imply that, despite failing
to reduce markers of global oxidative damage (DCFDA ﬂuores-
cence and protein carbonyl levels), MitoQ may have highly speciﬁc
protective effects on the ETC and mitochondrial membrane in this
Aβ-induced oxidative stress model.
Multiple lines of evidence have associated Aβ-induced toxicity,
AD, and oxidative stress [69]. Given its protective efﬁcacy in the
transgenic nematodes, we initially expected that MitoQ might
Fig. 5. MitoQ treatment did not affect mtDNA damage burden nor alter global energy metabolism. (A) Oxidative mtDNA damage levels as evaluated by RT-PCR assay and
expressed as lesions per 10 kb. Neither MitoQ nor dTPP altered oxidative mtDNA damage levels in CL2006 animals (p 4 0.5, ANOVA, mean7SEM), n ¼ 3 independent
experiments. (B) Steady-state ATP levels per animal on day 6 were not signiﬁcantly different between untreated control and MitoQ- and dTPP-treated animals (p 4 0.5,
ANOVA, mean7SEM), n ¼ 9 independent replicates. (C) Average oxygen consumption normalized to worm protein. There were no statistically signiﬁcant differences in the
oxygen consumption rate in the untreated control, MitoQ-and dTPP-treated animals (p 4 0.5, ANOVA, mean7SEM), n ¼ 9 independent replicates.
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exert its effects through modulation of global oxidative stress.
However, one should never assume that observed beneﬁcial
effects on lifespan and healthspan in response to exposure to a
compound are due to antioxidant effects without conﬁrmation
through biomarkers [44,70]. To determine the overall effect of
MitoQ on Aβ-induced oxidative stress in C. elegans, we therefore
conducted oxidative stress marker and damage assays. Surpris-
ingly, we found that MitoQ did not decrease ROS ﬂux, reduce
protein oxidation levels, or modulate levels of oxidative damage
in mtDNA.
Cardiolipin is a phospholipid that is exclusively found in the
inner mitochondrial membrane [71,72]. Because of its high con-
tent of polyunsaturated fatty acids and its location near a major
source of ROS production, cardiolipin is vulnerable to peroxidation
[71]. Recently, we reported that there is a signiﬁcant age-
dependent decline in cardiolipin species in C. elegans [45]. Loss
of cardiolipin may be one of the factors contributing to mitochon-
drial dysfunction in aging and may also contribute to mitochon-
drial dysfunction in neurodegenerative diseases. To further
investigate MitoQ's potential as a targeted antioxidant and its
possible protective effect on mitochondrial lipids, we therefore
characterized mitochondrial cardiolipin species in treated and
untreated animals. Our data indicate that administration of MitoQ
increases or protects the cardiolipin content of mitochondrial
membranes, suggesting that MitoQ may be effective at protecting
the mitochondrial matrix.
Damage to the cardiolipin contents of the inner mitochondrial
membrane can disrupt cardiolipin binding to cytochrome c, thus
affecting the activity of ETC complexes, particularly complex IV
[71]. Complex IV activity is consistently reported to be deﬁcient in
AD patients [24,73] and this may be of pathogenic signiﬁcance in
AD. Our results showed that MitoQ is very effective at improving
or protecting complex IV activity in CL2006. We anticipated that
this effect on complex IV might improve mitochondrial global
function, particularly metabolic energy availability. However,
administration of MitoQ did not affect the global energy avail-
ability as determined by ATP content and oxygen consumption
rate. This is surprising given the clear evidence that the ETC is
protected and that MitoQ-treated animals lived longer and were
healthier. It remains to be investigated how the protection of ETC
complexes may be beneﬁcial without affecting baseline energy
availability. Nevertheless, the protective effects observed, speciﬁ-
cally on the mitochondrial membrane, are likely to involve an
antioxidant mechanism, as dTPP alone did not modulate complex
IV activity of the transgenic nematodes.
MitoQ has been previously reported to have no signiﬁcant
positive effect on the lifespan of wildtype Drosophila [33]. This is
consistent with our ﬁndings in wildtype C. elegans, which demon-
strate that, in contrast to transgenic CL2006 animals, MitoQ did
not increase the lifespan of wildtype N2 animals. This lack of effect
in unstressed animals suggests that, although there is a possible
role for MitoQ as an intervention in disease states associated with
increased oxidative stress or mtDNA damage burden, it may not
function to modulate basic aging rate. We are aware that a closely
related mitochondria-targeted antioxidant moiety, plastoquinone,
has been reported to have efﬁcacy at protecting against a range of
age-dependent disorders in vivo [74]. However, further research is
needed to conﬁrm the reproducibility of these effects [75,76].
Together, the ﬁndings in the wildtype Drosophila and mutator mice
further suggest that mitochondria-targeted antioxidants probably
have protective effects in stressed animals, whereas effects on normal
aging remain to be shown.
The observation that MitoQ is able to delay Aβ-induced
paralysis in the transgenic nematodes is consistent with work
performed using Aβ-induced toxicity in transgenic mice [29]. In
these mice MitoQ was shown to have a protective effect, by
preventing the onset of AD-associated cognitive decline [29].
However, no lifespan study was reported. We also found that
MitoQ is able to protect or elevate complex IV activity in our AD
model. This is consistent with a study in azide-treated rats, in
which the authors demonstrate that a reduction in complex IV
activity is associated with learning impairment [24,77].
Energy production by mitochondria relies on functional ETC
enzyme complexes. Our study showed signiﬁcant elevation (or
protection against loss) of complex I activity in both MitoQ- and
dTPP-treated animals, though, we did not detect changes in ROS
production. ROS production in mitochondria depends, in non-
trivial ways, on key mitochondrial parameters, including oxygen
partial pressure, mitochondrial membrane potential, and the
redox state of the electron carriers in the ETC [58]. Due to the
complexity of mitochondrial and ROS homeodynamics, changes in
maximum complex I activity cannot be easily used to predict the
rate of production of ROS. Furthermore, it is important to realize
that the rate measured in the complex I assay is a maximum rate,
based on providing high levels of substrate, and may therefore be
signiﬁcantly different from the steady-state electron ﬂux through
complex I in vivo. This means that the observed increase in
complex I activity does not necessarily imply an increase in
superoxide production. The elevation of complex I activity in both
treatment groups is probably due to nonspeciﬁc effects of the dTPP
cation. For example, accumulation of lipophilic cations such as
dTPP within the mitochondria increases proton permeability of the
Fig. 6. Impact of MitoQ and dTPP on ETC activity. (A) Polarographic complex IV
activity assay was conducted and normalized to the mtDNA copy number of the
respective mitochondria extract. Complex IV activity was signiﬁcantly elevated
(ANOVA with Bonferroni's post-test, mean7SEM) in MitoQ-treated animals but
not in dTPP-treated animals and untreated-control, n ¼ 9 independent replicates.
(B) Rotenone-sensitive complex I activity was measured based on decrease in
ﬂuorescence of NADH and normalized to mtDNA copy number of the respective
mitochondria extract. A signiﬁcantly higher (ANOVA with Bonferroni's post-test,
mean7SEM) complex I activity level was detected in both MitoQ- and dTPP-
treated animals relative to untreated control animals, n ¼ 9 independent replicates.
*p o 0.05, **p o 0.01.
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mitochondrial inner membrane [78], meaning that the mitochon-
drial membrane potential may be reduced. This mitochondrial
depolarization can disrupt mitochondrial membrane integrity,
respiration, and ATP synthesis, which can eventually affect mito-
chondrial function through uncoupling [79]. This interpretation is
consistent with our ATP measurement, which showed that dTPP-
treated animals have a trend toward lower ATP content compared
to other treatment groups, albeit non-signiﬁcant. These data
illustrate the importance of including dTPP-treated control groups
in experiments aimed at determining the efﬁcacy of MitoQ or
similar compounds to ensure that all effects attributed to the
antioxidant are due to the antioxidant moiety rather than the mild
uncoupling or other effects of the targeting moiety (dTPP). How-
ever, further investigation is needed into the physiological effects
of dTPP. Data from chemical uncouplers such as FCCP [80,81], CCCP
[82], and DNP (unpublished) have sometimes shown a lifespan
extension effect. However, most of these studies are not accompanied
by strong biomarker data, proving that the lifespan effects are due to
reduced ROS damage secondary to mild mitochondrial uncoupling.
Given the overall uncertainty regarding the effects of mild uncoupling
on lifespan in C. elegans, we cannot therefore exclude the possibility
that some or all of the dTPP effects observed might be caused by a
physiological mechanism other than mild mitochondrial uncoupling.
Together our results suggest that mitochondria-targeted anti-
oxidants, such as MitoQ, may represent a promising strategy
against Aβ-induced toxicity and oxidative stress.
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Fig. 7. Effect of MitoQ administration on the content of the mitochondrial-speciﬁc lipid cardiolipin. (A) Administration of MitoQ increased total cardiolipin content of
mitochondrial membranes (p 4 0.05, ANOVA, mean7SEM), n ¼ 7 independent replicates. (B) A detailed lipidomics method was used to characterize various cardiolipin
species in the nematodes. Signiﬁcantly higher levels of unsaturated cardiolipin (20:4) species were detected in MitoQ-treated animals relative to untreated control
nematodes (comparison: control vs MitoQ, *p o 0.05, **p o 0.01, ANOVA with Tukey's post-test, mean7SEM), n ¼ 7 independent replicates.
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